{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:23:46Z","timestamp":1761578626185,"version":"3.37.3"},"reference-count":105,"publisher":"Informa UK Limited","issue":"3","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2018,4,3]]},"DOI":"10.1080\/00325481.2018.1436843","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T11:35:56Z","timestamp":1518003356000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option"],"prefix":"10.1080","volume":"130","author":[{"given":"Gregory S.","family":"Pokrywka","sequence":"first","affiliation":[{"name":"Baltimore Lipid Center \/ Johns Hopkins University School of Medicine, General Internal Medicine, Towson, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.002"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.APPGL"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000297"},{"issue":"1","key":"CIT0008","first-page":"e121","volume":"9","author":"Jacobson TA","year":"2015","journal-title":"J Clin Lipidol"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.05.001"},{"key":"CIT0010","first-page":"2245","volume":"38","author":"Landmesser U","year":"2017","journal-title":"Eur Heart J"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"CIT0016","unstructured":"Sanofi-Aventis U.S. LLC. Highlights of PRALUENT prescribing information 2017 cited 2017 Sep. Available from: http:\/\/products.sanofi.us\/praluent\/praluent.pdf."},{"key":"CIT0017","unstructured":"Amgen Inc. Highlights of Repatha prescribing information 2016 cited 2016 Jul. Available from: http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.ashx."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-014-0439-8"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1086\/500615"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1038\/ng1509"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1086\/507488"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1206"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.08.039"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301621"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R026658"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179564"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700443-JLR200"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1616623"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614062"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv707"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M061903"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.07.004"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609243"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114469"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx260"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30044-X"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.018"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.019"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870\u20131882.","DOI":"10.1001\/jama.2014.4030"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv028"},{"key":"CIT0048","first-page":"2996","volume":"36","author":"Kastelein JJ","year":"2015","journal-title":"Eur Heart J"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.004"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.006"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.043"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003421"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw388"},{"key":"CIT0056","first-page":"651","volume":"8","author":"Bell DA","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"CIT0057","unstructured":"FH Foundation. FH Foundation: CDC approves diagnosis codes for Familial Hypercholesterolemia Pasadena, CA, 2016. cited 2017 Aug 7. Available from: http:\/\/www.prnewswire.com\/news-releases\/fh-foundation-cdc-approves-diagnosis-codes-for-familial-hypercholesterolemia-300294067.html."},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.12.004"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12788"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13450"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00003-6"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12909"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13114"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0552-4"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.08.273"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P065334"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.07.028"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.08.072"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025233"},{"key":"CIT0074","unstructured":"US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs 2012. cited 2017 Jul 18. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293101.htm."},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.08.041"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-3115-3"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-10-201311190-00007"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.07.013"},{"key":"CIT0081","doi-asserted-by":"crossref","first-page":"e003153","DOI":"10.1161\/CIRCOUTCOMES.116.003153","volume":"10","author":"Khan AR","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"CIT0082","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. EBBINGHAUS: a cognitive study of patients enrolled in the FOURIER trial 2017. cited 2017 Mar 24. Available from: https:\/\/accscientificsession.acc.org\/."},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604304"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30396-5"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw292"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000180"},{"key":"CIT0087","unstructured":"US Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products. Guidance for industry 2016 cited 2017 Nov 17. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/UCM192750.pdf."},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh236"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90155-6"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.002"},{"key":"CIT0093","unstructured":"American College of Cardiology. American College of Cardiology statin intolerance [mobile application] 2015. cited 2017 Nov 20. Available from: http:\/\/www.acc.org\/StatinIntoleranceApp."},{"key":"CIT0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.003"},{"issue":"70","key":"CIT0095","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"2017","author":"Lloyd-Jones DM","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"CIT0096","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22535"},{"key":"CIT0097","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1284078"},{"key":"CIT0098","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169761"},{"key":"CIT0099","doi-asserted-by":"crossref","unstructured":"Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743\u2013753.","DOI":"10.1001\/jama.2016.11004"},{"key":"CIT0100","doi-asserted-by":"crossref","unstructured":"Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA. 2017;318:748\u2013750.","DOI":"10.1001\/jama.2017.9924"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2762"},{"key":"CIT0102","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3143"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.120"},{"key":"CIT0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.928"},{"key":"CIT0105","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx710"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2018.1436843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:48:06Z","timestamp":1660438086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2018.1436843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4,3]]}},"alternative-id":["10.1080\/00325481.2018.1436843"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2018.1436843","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"type":"print","value":"0032-5481"},{"type":"electronic","value":"1941-9260"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}